Atara Biotherapeutics, Inc.
ATRA
$15.63
$1.6511.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 188.67M | 199.73M | 128.94M | 100.44M | 62.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 188.67M | 199.73M | 128.94M | 100.44M | 62.39M |
| Cost of Revenue | 127.12M | 131.19M | 135.77M | 147.39M | 155.37M |
| Gross Profit | 61.55M | 68.54M | -6.83M | -46.95M | -92.98M |
| SG&A Expenses | 35.81M | 38.78M | 38.53M | 39.48M | 41.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 169.29M | 202.95M | 207.27M | 219.84M | 229.65M |
| Operating Income | 19.38M | -3.22M | -78.33M | -119.41M | -167.26M |
| Income Before Tax | 5.76M | -15.68M | -85.42M | -133.14M | -181.03M |
| Income Tax Expenses | -33.00K | -36.00K | -12.00K | 18.00K | 16.00K |
| Earnings from Continuing Operations | 5.80 | -15.64 | -85.40 | -133.16 | -181.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.80M | -15.64M | -85.40M | -133.16M | -181.05M |
| EBIT | 19.38M | -3.22M | -78.33M | -119.41M | -167.26M |
| EBITDA | 24.40M | 1.76M | -73.76M | -114.73M | -162.61M |
| EPS Basic | -0.39 | -3.69 | -12.87 | -25.66 | -39.12 |
| Normalized Basic EPS | 0.40 | -1.70 | -7.48 | -14.50 | -22.92 |
| EPS Diluted | -0.43 | -3.72 | -12.87 | -25.66 | -39.13 |
| Normalized Diluted EPS | 0.38 | -1.72 | -7.48 | -14.50 | -22.92 |
| Average Basic Shares Outstanding | 41.14M | 35.08M | 29.94M | 23.56M | 20.35M |
| Average Diluted Shares Outstanding | 41.34M | 35.17M | 29.94M | 23.56M | 20.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |